193 related articles for article (PubMed ID: 21745212)
1. Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants.
Thakur A; Sorenson C; Norkina O; Schalk D; Ratanatharathorn V; Lum LG
Transfusion; 2012 Jan; 52(1):63-75. PubMed ID: 21745212
[TBL] [Abstract][Full Text] [Related]
2. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
[TBL] [Abstract][Full Text] [Related]
4. Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.
Lum LG; Ramesh M; Thakur A; Mitra S; Deol A; Uberti JP; Pellett PE
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1012-22. PubMed ID: 22313635
[TBL] [Abstract][Full Text] [Related]
5. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.
Yano H; Thakur A; Tomaszewski EN; Choi M; Deol A; Lum LG
J Transl Med; 2014 Jul; 12():191. PubMed ID: 25008236
[TBL] [Abstract][Full Text] [Related]
7. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
Lum LG; Thakur A; Liu Q; Deol A; Al-Kadhimi Z; Ayash L; Abidi MH; Pray C; Tomaszewski EN; Steele PA; Schalk DL; Yano H; Mitchell A; Dufresne M; Uberti JP; Ratanatharathorn V
Biol Blood Marrow Transplant; 2013 Jun; 19(6):925-33. PubMed ID: 23529012
[TBL] [Abstract][Full Text] [Related]
8. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
[TBL] [Abstract][Full Text] [Related]
9. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
[TBL] [Abstract][Full Text] [Related]
10. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
Thakur A; Scholler J; Schalk DL; June CH; Lum LG
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation.
Robinson KL; Ayello J; Hughes R; van de Ven C; Issitt L; Kurtzberg J; Cairo MS
Exp Hematol; 2002 Mar; 30(3):245-51. PubMed ID: 11882362
[TBL] [Abstract][Full Text] [Related]
12. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B
Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665
[TBL] [Abstract][Full Text] [Related]
13. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
[TBL] [Abstract][Full Text] [Related]
14. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
15. Effect of interleukin-15 on anti-CD3/anti-CD28 induced apoptosis of umbilical cord blood CD4+ T cells.
Lin SJ; Yu JC; Cheng PJ; Hsiao SS; Kuo ML
Eur J Haematol; 2003 Dec; 71(6):425-32. PubMed ID: 14703692
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.
Yankelevich M; Kondadasula SV; Thakur A; Buck S; Cheung NK; Lum LG
Pediatr Blood Cancer; 2012 Dec; 59(7):1198-205. PubMed ID: 22707078
[TBL] [Abstract][Full Text] [Related]
17. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
[TBL] [Abstract][Full Text] [Related]
19. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
20. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]